These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 30061283

  • 1. Population Pharmacokinetic Analyses for Ertapenem in Subjects with a Wide Range of Body Sizes.
    Lakota EA, Landersdorfer CB, Zhang L, Nafziger AN, Bertino JS, Bhavnani SM, Forrest A.
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061283
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.
    Narwal R, Roskos LK, Robbie GJ.
    Clin Pharmacokinet; 2013 Nov; 52(11):1017-27. PubMed ID: 23754736
    [Abstract] [Full Text] [Related]

  • 4. Population Pharmacokinetic Analysis of Dorzagliatin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus.
    Wang K, Feng L, Zhang J, Zou Q, Xu F, Sun Z, Tang F, Chen L.
    Clin Pharmacokinet; 2023 Oct; 62(10):1413-1425. PubMed ID: 37537410
    [Abstract] [Full Text] [Related]

  • 5. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE, Würthwein G, Joachim B, Boddy AV, Krischke M, Fuhr U, Thompson PA, Jörger M, Schellens JH, Hempel G.
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007.
    McLeay SC, Morrish GA, Kirkpatrick CM, Green B.
    Clin Pharmacokinet; 2012 May 01; 51(5):319-30. PubMed ID: 22439649
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Population pharmacokinetics and probability of target attainment of ertapenem administered by subcutaneous or intravenous route in patients with bone and joint infection.
    Goutelle S, Valour F, Gagnieu MC, Laurent F, Chidiac C, Ferry T, Lyon Bone and Joint Infection Study Group.
    J Antimicrob Chemother; 2018 Apr 01; 73(4):987-994. PubMed ID: 29244077
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Population pharmacokinetic analysis of lanicemine (AZD6765), an NMDA channel blocker, in healthy subjects and patients with major depressive disorder.
    Agbo F, Bui KH, Zhou D.
    J Clin Pharm Ther; 2017 Oct 01; 42(5):539-546. PubMed ID: 28474366
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Evaluation of Aztreonam Dosing Regimens in Patients With Normal and Impaired Renal Function: A Population Pharmacokinetic Modeling and Monte Carlo Simulation Analysis.
    Xu H, Zhou W, Zhou D, Li J, Al-Huniti N.
    J Clin Pharmacol; 2017 Mar 01; 57(3):336-344. PubMed ID: 27530649
    [Abstract] [Full Text] [Related]

  • 15. Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults.
    Chen M, Nafziger AN, Drusano GL, Ma L, Bertino JS.
    Antimicrob Agents Chemother; 2006 Apr 01; 50(4):1222-7. PubMed ID: 16569832
    [Abstract] [Full Text] [Related]

  • 16. Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.
    Mittapalli RK, Nuthalapati S, Shepherd SP, Xiong H.
    Cancer Chemother Pharmacol; 2017 Mar 01; 79(3):587-594. PubMed ID: 28247011
    [Abstract] [Full Text] [Related]

  • 17. Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration.
    Burkhardt O, Kumar V, Katterwe D, Majcher-Peszynska J, Drewelow B, Derendorf H, Welte T.
    J Antimicrob Chemother; 2007 Feb 01; 59(2):277-84. PubMed ID: 17185298
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Population pharmacokinetic analysis of meropenem in Japanese adult patients.
    Muro T, Sasaki T, Hosaka N, Umeda Y, Takemoto S, Yamamoto H, Kamimura H, Higuchi S, Karube Y.
    J Clin Pharm Ther; 2011 Apr 01; 36(2):230-6. PubMed ID: 21366653
    [Abstract] [Full Text] [Related]

  • 20. Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin.
    Jolling K, Perez Ruixo JJ, Hemeryck A, Vermeulen A, Greway T.
    Eur J Pharm Sci; 2005 Apr 01; 24(5):465-75. PubMed ID: 15784336
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.